BR112013032193A2 - composição e formulação compreendendo iduronato-2-sulfatase recombinante humana e preparação do método da mesma - Google Patents

composição e formulação compreendendo iduronato-2-sulfatase recombinante humana e preparação do método da mesma

Info

Publication number
BR112013032193A2
BR112013032193A2 BR112013032193A BR112013032193A BR112013032193A2 BR 112013032193 A2 BR112013032193 A2 BR 112013032193A2 BR 112013032193 A BR112013032193 A BR 112013032193A BR 112013032193 A BR112013032193 A BR 112013032193A BR 112013032193 A2 BR112013032193 A2 BR 112013032193A2
Authority
BR
Brazil
Prior art keywords
sulfatase
formulation
composition
recombinant human
method preparation
Prior art date
Application number
BR112013032193A
Other languages
English (en)
Inventor
Seo Jinwook
Mun Son Jong
Hoon Paik Sang
Jin Thong-Gyu
Kyung Chung Yo
Woon Choi Yong
Kim Yong-Chul
Chang Park Yoo
Original Assignee
Green Cross Corp
Medigenebio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46716009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013032193(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Green Cross Corp, Medigenebio Corp filed Critical Green Cross Corp
Publication of BR112013032193A2 publication Critical patent/BR112013032193A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112013032193A 2011-06-24 2012-06-15 composição e formulação compreendendo iduronato-2-sulfatase recombinante humana e preparação do método da mesma BR112013032193A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500994P 2011-06-24 2011-06-24
KR1020120012718A KR101158673B1 (ko) 2011-06-24 2012-02-08 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
PCT/KR2012/004734 WO2012177020A2 (en) 2011-06-24 2012-06-15 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

Publications (1)

Publication Number Publication Date
BR112013032193A2 true BR112013032193A2 (pt) 2017-11-21

Family

ID=46716009

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013032193A BR112013032193A2 (pt) 2011-06-24 2012-06-15 composição e formulação compreendendo iduronato-2-sulfatase recombinante humana e preparação do método da mesma

Country Status (28)

Country Link
US (2) US9206402B2 (pt)
EP (1) EP2723369B2 (pt)
JP (2) JP5844459B2 (pt)
KR (2) KR101158673B1 (pt)
CN (1) CN103635203B (pt)
AU (2) AU2012274215B2 (pt)
BR (1) BR112013032193A2 (pt)
CA (1) CA2839674C (pt)
CO (1) CO6862105A2 (pt)
CY (1) CY1117861T1 (pt)
DK (1) DK2723369T4 (pt)
EA (1) EA026499B1 (pt)
ES (1) ES2575377T5 (pt)
FI (1) FI2723369T4 (pt)
HK (1) HK1195731A1 (pt)
HR (1) HRP20160490T4 (pt)
HU (1) HUE027431T2 (pt)
IL (1) IL230120B (pt)
MX (1) MX341946B (pt)
MY (1) MY166647A (pt)
PE (1) PE20140734A1 (pt)
PL (1) PL2723369T5 (pt)
PT (1) PT2723369E (pt)
RS (1) RS54822B2 (pt)
SI (1) SI2723369T2 (pt)
SM (1) SMT201600194B (pt)
UA (1) UA109949C2 (pt)
WO (1) WO2012177020A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CN106153745B (zh) * 2015-03-31 2020-11-10 三生国健药业（上海）股份有限公司 抗体蛋白二硫键配对分析方法
CN106153746B (zh) * 2015-03-31 2020-11-06 三生国健药业（上海）股份有限公司 IgG2型单抗二硫键配对分析方法
CN106153744B (zh) * 2015-03-31 2020-11-10 三生国健药业（上海）股份有限公司 融合蛋白二硫键配对分析方法
KR20170004814A (ko) * 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
SG11201805598WA (en) * 2015-12-30 2018-07-30 Green Cross Corp Methods and compositions for treating hunter syndrome
US20190055513A1 (en) * 2016-02-22 2019-02-21 Agency For Science, Technology And Research Cell culture medium
KR20190139951A (ko) 2017-04-14 2019-12-18 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
WO2019022563A2 (ko) * 2017-07-28 2019-01-31 한미약품 주식회사 이두로네이트 2-설파타제 결합체
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
KR20190136271A (ko) 2018-05-30 2019-12-10 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
EP3846780A4 (en) * 2018-09-05 2022-11-30 Sangamo Therapeutics, Inc. ENZYMATIC TESTS FOR QUANTIFICATION OF THERAPY IN PATIENTS WITH MUCOPOLYSACCHARIDOSE TYPE I OR II
EP3826664A4 (en) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
AU2004210936C1 (en) 2003-02-11 2010-12-02 Takeda Pharmaceutical Company Limited Diagnosis and treatment of Multiple Sulfatase Deficiency and other using a Formylglycine Generating Enzyme (FGE)
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제

Also Published As

Publication number Publication date
EA026499B1 (ru) 2017-04-28
EA201490149A1 (ru) 2014-09-30
CY1117861T1 (el) 2017-05-17
JP2016056179A (ja) 2016-04-21
AU2016201487B2 (en) 2017-10-19
KR101158673B1 (ko) 2012-07-03
EP2723369A4 (en) 2014-12-24
SMT201600194B (it) 2016-08-31
EP2723369B2 (en) 2023-05-10
UA109949C2 (uk) 2015-10-26
MY166647A (en) 2018-07-18
CA2839674C (en) 2018-04-24
ES2575377T5 (es) 2023-10-26
US20150320843A1 (en) 2015-11-12
WO2012177020A2 (en) 2012-12-27
AU2016201487A1 (en) 2016-03-24
PL2723369T3 (pl) 2016-09-30
RS54822B2 (sr) 2023-09-29
PT2723369E (pt) 2016-06-03
MX341946B (es) 2016-09-08
CN103635203A (zh) 2014-03-12
RS54822B1 (sr) 2016-10-31
WO2012177020A3 (en) 2013-04-04
SI2723369T1 (sl) 2016-09-30
AU2012274215A1 (en) 2014-02-20
CN103635203B (zh) 2016-06-08
EP2723369A2 (en) 2014-04-30
PE20140734A1 (es) 2014-07-04
JP6000432B2 (ja) 2016-09-28
KR20160030591A (ko) 2016-03-21
HUE027431T2 (en) 2016-09-28
US20140242059A1 (en) 2014-08-28
AU2012274215B2 (en) 2015-12-10
DK2723369T3 (en) 2016-06-13
US9206402B2 (en) 2015-12-08
US9249397B2 (en) 2016-02-02
MX2013015127A (es) 2014-06-11
HK1195731A1 (zh) 2014-11-21
CA2839674A1 (en) 2012-12-27
FI2723369T4 (fi) 2023-08-31
DK2723369T4 (da) 2023-07-24
KR101910124B1 (ko) 2018-10-19
HRP20160490T1 (hr) 2016-08-12
IL230120B (en) 2020-09-30
WO2012177020A9 (en) 2013-02-14
PL2723369T5 (pl) 2024-02-05
ES2575377T3 (es) 2016-06-28
NZ620284A (en) 2015-11-27
JP2014520143A (ja) 2014-08-21
HRP20160490T4 (hr) 2023-09-15
CO6862105A2 (es) 2014-02-10
EP2723369B1 (en) 2016-04-13
JP5844459B2 (ja) 2016-01-20
SI2723369T2 (sl) 2023-08-31

Similar Documents

Publication Publication Date Title
BR112013032193A2 (pt) composição e formulação compreendendo iduronato-2-sulfatase recombinante humana e preparação do método da mesma
CL2014000927A1 (es) Proteinas naglu humana recombinante y usos de la misma
BR112014009634A2 (pt) preparação e agente terapêutico
CO6852076A2 (es) Composiciones farmacéuticas inhalables
BR112014012753A2 (pt) composição para pele e método de hidratação da pele
BR112014006291A2 (pt) composição e utilização da composição
DK2525798T3 (da) Anæstetisk formulering
BR112013021274A2 (pt) composição cosmética botânica bioativa, formulação cosmética botânica bioativa, e método para preparar uma composição cosmética botânica bioativa
BR112013014644A2 (pt) composição farmacêutica e complexo
GB2505860B (en) Aripiprazole medicament formulation and preparation method therefor
BR112014010290A2 (pt) composição farmacêutica, métodos, composições e usos
DK2529756T3 (da) Risperidon- og/eller paliperidon-implantatformulering
BR112014004936A2 (pt) polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo
BR112014010450A2 (pt) composição e método
BR112014004144A2 (pt) composição de ionômero antimicrobiana e usos da mesma
CO6910193A2 (es) Derivados de anilina, su preparación y su aplicación terapéutica
BR112014005254A2 (pt) composições antimicrobianas e usos das mesmas
SMT201500005B (it) Composizione framaceutica inalabile
BR112013017267A2 (pt) formulação de lipossomas, suspensão e composição farmacêutica
BR112014010860A2 (pt) composição e método
BR112013033472A2 (pt) derivado de camptotecina e método de preparação do mesmo e composição farmacêutica e aplicação
EP2915530A4 (en) COMPOSITION FOR THE KILLING OF ANIMAL PARASITES AND METHOD FOR THE KILLING OF ANIMAL PARASITES
BR112015002646A2 (pt) composto e composição farmacêutica
BR112014009501A2 (pt) organogel e com´posição cosmética
BR112013022530A2 (pt) método terapêutico homeopático e composições

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]